血清鳞状细胞癌抗原与宫颈鳞状细胞癌患者复发及生存的相关性:系统综述与荟萃分析
该系统综述与荟萃分析纳入61项研究,评估治疗前后血清鳞状细胞癌抗原(SCC-Ag)与宫颈鳞状细胞癌复发和死亡风险的关联。治疗前高SCC-Ag者复发风险RR为2.44(95%CI:1.91,3.13),死亡风险RR为3.66(95%CI:2.24,5.98)。作者认为该标志物可能有助于监测疾病进展。
要点
- 治疗前高SCC-Ag与复发风险升高相关,合并RR为2.44(95%CI:1.91,3.13)。
- 治疗前高SCC-Ag与死亡风险升高相关,合并RR为3.66(95%CI:2.24,5.98)。
- 治疗后SCC-Ag与复发和死亡也呈类似趋势,合并RR分别为3.91和见原文。
核心结论
- 血清SCC-Ag与新诊断宫颈癌的复发和死亡持续相关,该标志物可能有助于监测宫颈癌患者的疾病进展。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE和Scopus数据库至2016年6月29日,共纳入61项评估SCC-Ag对宫颈癌患者复发和死亡影响的研究。
- 数据提取由两名评价员独立完成,合并效应量包括风险比(RR)、风险比(HR)和未标准化均数差(USMD)。
主要发现
- 治疗前高vs低血清SCC-Ag与复发的合并RR为2.44(95%CI:1.91,3.13),合并HR为2.23(95%CI:2.03,2.45),合并USMD为-7.7(95%CI:-31.7,16.4)。
- 治疗后高vs低血清SCC-Ag与复发的合并RR为3.91(95%CI:2.96,5.16),合并HR为3.14(95%CI:1.29,7.65),合并USMD为3.2(95%CI:-10.6,17.0)。
- 治疗前高vs低血清SCC-Ag与死亡的合并RR为3.66(95%CI:2.24,5.98),合并HR为2.50(95%CI:1.85,3.37),合并USMD为7.10(95%CI:4.26,9.94)。
- 治疗后血清SCC-Ag对死亡的影响也反映类似趋势。
临床怎么用
- 作者认为血清SCC-Ag可能有助于监测宫颈癌患者的疾病进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this systematic review and meta-analysis was to pool association effects of serum squamous cell carcinoma antigen (SCC-Ag) on recurrence and mortality in mainly squamous cell cervical cancer patients. METHODS: MEDLINE and Scopus databases were searched up to June 29, 2016. Studies assessing effects of SCC-Ag on recurrence and death in cervical cancer patients were included. Data extraction was independently performed by two reviewers. A meta-analysis was applied for pooling the effects (i.e., risk ratio (RR), hazard ratio (HR), and unstandardized mean difference (USMD)) of SCC-Ag measured before and after treatment on recurrence and death. RESULTS: A total of 61 studies were included. For pretreatment SCC-Ag and recurrence, the pooled RR, HR, and USMD for high versus low serum SCC-Ag were 2.44(95% CI: 1.91, 3.13), 2.23(95% CI: 2.03, 2.45), -7.7(95% CI: -31.7, 16.4), respectively. The corresponding effects for the posttreatment period were 3.91(95% CI: 2.96, 5.16), 3.14(95% CI: 1.29, 7.65), and 3.2(95% CI: -10.6, 17.0), respectively. In addition, patients with high level of pretreatment serum SCC-Ag were also at a higher risk for death than patients with low serum SCC-Ag with a pooled RR of 3.66(95% CI: 2.24, 5.98), pooled HR of 2.50(95% CI: 1.85, 3.37), and pooled USMD of 7.10(95% CI: 4.26, 9.94). The posttreatment serum SCC-Ag effects also reflected a similar trend. CONCLUSIONS: The serum SCC-Ag was consistently associated with recurrence and mortality of newly diagnosed cervical cancer. This marker may be useful in monitoring disease progression in cervical cancer patients. Prospero registration number is: CRD42016044024.
引用
- Charakorn C, Thadanipon K, Chaijindaratana S, et al. The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis. Gynecol Oncol. 2018. PMID: 29606483. doi:10.1016/j.ygyno.2018.03.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。